A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
Guanfacine Extended Release (GXR) is being evaluated for its efficacy in reducing aggression and self-injurious behavior in individuals with Prader-Willi Syndrome (PWS). This clinical trial, sponsored by Maimonides Medical Center, addresses a significant unmet need in the management of behavioral symptoms associated with PWS, a genetic disorder affecting appetite and behavior. If successful, GXR could capture a niche market within the pediatric and adolescent populations suffering from PWS, potentially expanding its use beyond its current FDA-approved indications for hypertension and ADHD. The competitive landscape includes other behavioral interventions and pharmacotherapies, but GXR's specific targeting of aggression and self-injury in PWS may provide a unique selling proposition. Diligence should focus on the trial's safety profile and metabolic effects, as these will be critical for market acceptance and physician adoption.
Indication: Prader-Willi Syndrome
Modality: small molecule
Target: Adrenergic alpha-2 Receptor Agonist
Sponsor: Maimonides Medical Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Adrenergic alpha-2 Receptor Agonist
View original source fields
Condition raw: Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Condition normalized: Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Adrenergic alpha-2 Receptor Agonist
Target normalized: Adrenergic alpha-2 Receptor Agonist